AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Enanta Pharmaceuticals Announces Passing of Chief Financial and Administrative Officer Paul J. Mellett Jr.
ByAinvest
Wednesday, Sep 3, 2025 6:03 am ET1min read
Enanta Pharmaceuticals has announced the passing of its longtime Chief Financial and Administrative Officer, Paul J. Mellett Jr. The company's CEO, Jay R. Luly, praised Mellett for his leadership, generosity, and dedication to the company. Mellett joined Enanta in 2003 and played a key role in the company's growth and success, including the development of medications for chronic hepatitis C virus infection. He will be remembered for his humility, compassion, and authentic relationships with colleagues.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has announced the passing of its longtime Chief Financial and Administrative Officer, Paul J. Mellett Jr. The company's CEO, Jay R. Luly, praised Mellett for his leadership, generosity, and dedication to the company. Mellett joined Enanta in 2003 and played a key role in the company's growth and success, including the development of medications for chronic hepatitis C virus infection. He will be remembered for his humility, compassion, and authentic relationships with colleagues [1].Mellett's career spanned nearly 50 years, with notable positions at Essential Therapeutics, GelTex Pharmaceuticals, and Marshall Contractors. He was also a board member of Norwood Hospital and Big Brothers Big Sisters of Boston, demonstrating his commitment to service. His legacy at Enanta includes establishing the finance department, leading the company's initial public offering in 2013, and advancing strategic partnerships, such as the collaboration with Abbott (now AbbVie) that resulted in the commercialization of VIEKIRA PAK® and MAVYRET®/MAVIRET®, which have cured more than one million patients globally [1].
In light of Mellett's passing, Harry R. Trout, III, and Kathleen S. Capps, CPA, have been appointed as the Company’s principal financial officer and principal accounting officer, respectively, on an interim basis [1].
References:
[1] https://www.stocktitan.net/news/ENTA/enanta-pharmaceuticals-announces-the-passing-of-its-beloved-and-dlzke19fs1w5.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet